The Respiratory Pathogen Array provides rapid, high sensitivity detection of 22 bacterial and viral respiratory pathogens simultaneously from a single patient sample. Established Biochip Array Technology has enabled the consolidation of proteomic and genomic analysis onto one platform.

• Influenza A
• Influenza B
• Human respiratory syncytial virus A
• Human respiratory syncytial virus B
• Human parainfluenza virus 1
• Human parainfluenza virus 2
• Human parainfluenza virus 3
• Human parainfluenza virus 4
• Human coronavirus 229E/NL63
• Human coronavirus OC43/HKU1
• Mycoplasma pneumoniae
• Human rhinovirus A/B
• Human enterovirus A/B/C
• Human adenovirus B/C/E
• Human bocavirus 1/2/3
• Human metapneumovirus
• Chlamydophila pneumoniae
• Legionella pneumophila
• Haemophilus influenza
• Staphylococcus aureus
• Streptococcus pneumoniae
• Moraxella catarrhalis

Benefits of the Respiratory Pathogen Array

• Multiplexing saves time and cost associated with single analyte testing
• Viral and bacterial infections detected saving time on duplicate testing
• Increased specificity through biochip hybridisation
• Complete profile of pathogens identifies secondary or multiple infections
• Prevents spread of infection through early intervention and enables appropriate treatment to begin quicker
• Reduces antibiotic misuse
• Reduced sample requirements

The Respiratory Pathogen Array enables rapid, comprehensive screening of a wide range of potentially life threatening infectious respiratory pathogens. Providing cost effective, efficient testing, the Respiratory Pathogen Array offers complete test consolidation onto one platform.